etoposide has been researched along with salinomycin in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Chae, M; Kang, HS; Kim, HS; Kim, JH; Kim, WK; Kim, YJ; Yoon, S | 1 |
2 other study(ies) available for etoposide and salinomycin
Article | Year |
---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Hep G2 Cells; Humans; In Situ Nick-End Labeling; Proteasome Endopeptidase Complex; Pyrans; Sarcoma; Uterine Neoplasms | 2011 |